Investigational Drug May Reduce Involuntary Movementsin People with Parkinson's Disease
Tuesday, April 12, 2011 - 12:00
in Health & Medicine
Results of the first randomized, placebo-controlled long-term clinical trial show the investigational drug safinamide may reduce dyskinesia or involuntary movements in mid-to-late stage Parkinson's disease. The findings will be presented as late-breaking research at the 63rd Annual Meeting of the American Academy of Neurology, April 9-16, 2011, in Honolulu.